Search

Your search keyword '"Tommy Rampling"' showing total 61 results

Search Constraints

Start Over You searched for: Author "Tommy Rampling" Remove constraint Author: "Tommy Rampling"
61 results on '"Tommy Rampling"'

Search Results

1. Monkeypox virus-infected individuals mount comparable humoral immune responses as Smallpox-vaccinated individuals

2. COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2Research in context

3. Comparison of new and emerging SARS-CoV-2 variant transmissibility through active contact testing. A comparative cross-sectional household seroprevalence study.

4. Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial

5. SARS-CoV-2 lineage B.1.1.7 is associated with greater disease severity among hospitalised women but not men: multicentre cohort study

6. International Biological Reference Preparations for Epidemic Infectious Diseases

7. How achievable are COVID-19 clinical trial recruitment targets? A UK observational cohort study and trials registry analysis

8. Characterization of Antigenic MHC-Class-I-Restricted T Cell Epitopes in the Glycoprotein of Ebolavirus

9. Therapeutic Monoclonal Antibodies for Ebola Virus Infection Derived from Vaccinated Humans

10. CXCR3+ T Follicular Helper Cells Induced by Co-Administration of RTS,S/AS01B and Viral-Vectored Vaccines Are Associated With Reduced Immunogenicity and Efficacy Against Malaria

11. First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children.

12. Activation-induced Markers Detect Vaccine-Specific CD4+ T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials

13. Use of cidofovir in a patient with severe mpox and uncontrolled HIV infection

14. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY)

16. Clinical features and management of individuals admitted to hospital with monkeypox and associated complications across the UK: a retrospective cohort study

17. Neonatal Monkeypox Virus Infection

18. Corrigendum to 'Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial' [J Infect 84(6) (2022) 795–813, 5511]

19. Analogous humoral antigen recognition between Monkeypox-infected and Smallpox-vaccinated individuals

20. Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE):interim analysis of a randomised, controlled, phase 3, immunobridging trial

21. Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial

23. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

24. Demographics and Outcomes of Initial Phase of COVID-19 Medicines Delivery Units Across 4 UK Centers During Peak B1.1.529 Omicron Epidemic: A Service Evaluation

25. Short durations of corticosteroids for hospitalised COVID-19 patients are associated with a high readmission rate

26. Clinical features and management of human monkeypox: a retrospective observational study in the UK

27. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

28. Immunogenicity and Reactogenicity of BNT162b2 and mRNA1273 COVID-19 Vaccines Given as Fourth Dose Boosters in the COV-BOOST Randomised Trial Following Two Doses of ChAdOx1 nCov-19 or BNT162b2 and a Third Dose of BNT162b2

30. Demographics and Outcomes of COVID-19 Medicines Delivery Units Across 4 UK Centres During the Initial B1.1.529 Omicron Epidemic: A Service Evaluation

31. Clinical Features and Management of Individuals Hospitalised with Monkeypox and Associated Complications in the UK: A Retrospective Analysis Across 16 Hospitals

32. Experience of a novel community testing programme for COVID-19 in London: Lessons learnt

33. Clinical and Economic Impact of Implementing OVIVA Criteria on Patients With Bone and Joint Infections in Outpatient Parenteral Antimicrobial Therapy

34. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

35. The monkeypox case definition in the UK is broad

36. Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID-19 with B-cell malignancies

37. Family cluster of three cases of monkeypox imported from Nigeria to the United Kingdom, May 2021

38. Low seropositivity and sub-optimal neutralisation rates in patients fully vaccinated against COVID-19 with B cell malignancies

39. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

40. Therapeutic Monoclonal Antibodies for Ebola Virus Infection Derived from Vaccinated Humans

41. Genomic Characteristics and Clinical Impact of the Emergent SARS-CoV-2 B.1.1.7 Lineage in North Central London, November to December 2020

42. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

43. A cohort study of 30 day mortality after NON-EMERGENCY surgery in a COVID-19 cold site

44. How achievable are COVID-19 clinical trial recruitment targets? A UK observational cohort study and trials registry analysis

45. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study

46. Systematic evaluation and external validation of 22 prognostic models among hospitalised adults with COVID-19: An observational cohort study

47. Nosocomial Transmission of Coronavirus Disease 2019: A Retrospective Study of 66 Hospital-acquired Cases in a London Teaching Hospital

48. Characterisation of antigenic MHC Class I-restricted T cell epitopes in the glycoprotein of Ebolavirus

49. Imported malaria: key messages in an era of elimination

50. Normal nutritional function

Catalog

Books, media, physical & digital resources